Trafermin

Trafermin
Clinical data
Trade namesFiblast
Other namesCAB-2001; Recombinant human basic fibroblast growth factor; rhbFGF; 2-155-Basic fibroblast growth factor (human clone lambdaKB7/lambdaHFL1 precursor reduced)
Routes of
administration		Topical (spray)[1]
ATC code
Identifiers
CAS Number
PubChem SID
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC764H1201N217O219S6
Molar mass17122.67 g·mol−1

Trafermin (brand name Fiblast), also known as recombinant human basic fibroblast growth factor (rhbFGF), is a recombinant form of human basic fibroblast growth factor (bFGF) which is marketed in Japan as a topical spray for the treatment of skin ulcers.[2][3][1] It is also currently in preregistration for the treatment of periodontitis.[2][4] As a recombinant form of bFGF, trafermin is a potent agonist of the FGFR1, FGFR2, FGFR3, and FGFR4.[5][6] The drug has been marketed in Japan since June 2001.[citation needed]

  1. ^ a b Han SK (15 September 2015). "Growth Factor Therapy". Innovations and Advances in Wound Healing. Springer. pp. 206–. ISBN 978-3-662-46587-5.
  2. ^ a b "Trafermin - Kaken Pharmaceutical". AdisInsight. Springer Nature Switzerland AG.
  3. ^ "Trafermin". Drugs.com.
  4. ^ Kitamura M, Akamatsu M, Kawanami M, Furuichi Y, Fujii T, Mori M, et al. (April 2016). "Randomized Placebo-Controlled and Controlled Non-Inferiority Phase III Trials Comparing Trafermin, a Recombinant Human Fibroblast Growth Factor 2, and Enamel Matrix Derivative in Periodontal Regeneration in Intrabony Defects". Journal of Bone and Mineral Research. 31 (4): 806–814. doi:10.1002/jbmr.2738. PMID 26547659.
  5. ^ Barnard JA, McHugh KM (10 May 2006). "Growth Factors in the Gastrointestinal Tract". In Barrett KE, Ghishan FK, Merchant JL, Said HM, Wood JD (eds.). Physiology of the Gastrointestinal Tract. Academic Press. pp. 216–. ISBN 978-0-08-045615-7.
  6. ^ Hamid M. Said (4 July 2012). Physiology of the Gastrointestinal Tract, Two Volume Set. Academic Press. pp. 235–. ISBN 978-0-12-382027-3.